Based on these results, we propose here a new immunotherapeutic approach for B-CLL, based on the simultaneous targeted transfer of functional CD154 and the EBV protein gp350 onto malignant cells using exosomes. The gene discussed is CD40LG; the disease is B-cell chronic lymphocytic leukemia.